Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.

Abstract

JAK proteins have been linked with survival and proliferation of multiple myeloma (MM) cells; therefore, JAK inhibition could be a therapeutic strategy for MM. We evaluated JAK1 and JAK2 expression in MM patients and the effects of JAK/STAT pathway inhibition on apoptosis, cell cycle, gene and protein expression in RPMI-8226 and U266 MM cell lines. 57% of… (More)
DOI: 10.1016/j.canlet.2017.06.016

Topics

Cite this paper

@article{Oliveira2017AntimyelomaEO, title={Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.}, author={Mariana G de Oliveira and Veruska L. Fook-Alves and Angela I P Eugenio and Rodrigo Carlini Fernando and Luiz Felipe G Sanson and Mariana F de Carvalho and Walter M. T. Braga and Faith Elizabeth Davies and Gisele W. B. Colleoni}, journal={Cancer letters}, year={2017}, volume={403}, pages={206-215} }